Xenon Pharmaceuticals (XENE) Competitors $39.34 +0.49 (+1.26%) (As of 11/20/2024 ET) Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends XENE vs. SUPN, SAGE, VYGR, OVID, MRNS, PCVX, CTLT, SRPT, RVMD, and QGENShould you be buying Xenon Pharmaceuticals stock or one of its competitors? The main competitors of Xenon Pharmaceuticals include Supernus Pharmaceuticals (SUPN), Sage Therapeutics (SAGE), Voyager Therapeutics (VYGR), Ovid Therapeutics (OVID), Marinus Pharmaceuticals (MRNS), Vaxcyte (PCVX), Catalent (CTLT), Sarepta Therapeutics (SRPT), Revolution Medicines (RVMD), and Qiagen (QGEN). These companies are all part of the "medical" sector. Xenon Pharmaceuticals vs. Supernus Pharmaceuticals Sage Therapeutics Voyager Therapeutics Ovid Therapeutics Marinus Pharmaceuticals Vaxcyte Catalent Sarepta Therapeutics Revolution Medicines Qiagen Supernus Pharmaceuticals (NASDAQ:SUPN) and Xenon Pharmaceuticals (NASDAQ:XENE) are both medical companies, but which is the superior investment? We will contrast the two companies based on the strength of their community ranking, risk, dividends, earnings, profitability, valuation, media sentiment, institutional ownership and analyst recommendations. Which has preferable valuation & earnings, SUPN or XENE? Supernus Pharmaceuticals has higher revenue and earnings than Xenon Pharmaceuticals. Xenon Pharmaceuticals is trading at a lower price-to-earnings ratio than Supernus Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioSupernus Pharmaceuticals$607.52M3.28$1.32M$1.0733.76Xenon Pharmaceuticals$9.43M318.06-$182.39M-$2.82-13.95 Does the MarketBeat Community believe in SUPN or XENE? Supernus Pharmaceuticals received 55 more outperform votes than Xenon Pharmaceuticals when rated by MarketBeat users. Likewise, 72.99% of users gave Supernus Pharmaceuticals an outperform vote while only 69.90% of users gave Xenon Pharmaceuticals an outperform vote. CompanyUnderperformOutperformSupernus PharmaceuticalsOutperform Votes47372.99% Underperform Votes17527.01% Xenon PharmaceuticalsOutperform Votes41869.90% Underperform Votes18030.10% Does the media favor SUPN or XENE? In the previous week, Xenon Pharmaceuticals had 24 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 28 mentions for Xenon Pharmaceuticals and 4 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 1.50 beat Xenon Pharmaceuticals' score of 0.07 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Supernus Pharmaceuticals 4 Very Positive mention(s) 0 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Xenon Pharmaceuticals 6 Very Positive mention(s) 2 Positive mention(s) 3 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral Do institutionals & insiders have more ownership in SUPN or XENE? 95.5% of Xenon Pharmaceuticals shares are owned by institutional investors. 9.3% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 5.5% of Xenon Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Which has more volatility & risk, SUPN or XENE? Supernus Pharmaceuticals has a beta of 0.86, meaning that its stock price is 14% less volatile than the S&P 500. Comparatively, Xenon Pharmaceuticals has a beta of 1.25, meaning that its stock price is 25% more volatile than the S&P 500. Is SUPN or XENE more profitable? Supernus Pharmaceuticals has a net margin of 9.16% compared to Xenon Pharmaceuticals' net margin of 0.00%. Supernus Pharmaceuticals' return on equity of 7.79% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Supernus Pharmaceuticals9.16% 7.79% 5.67% Xenon Pharmaceuticals N/A -24.69%-23.68% Do analysts rate SUPN or XENE? Supernus Pharmaceuticals presently has a consensus price target of $36.00, indicating a potential downside of 0.33%. Xenon Pharmaceuticals has a consensus price target of $57.45, indicating a potential upside of 46.05%. Given Xenon Pharmaceuticals' stronger consensus rating and higher probable upside, analysts clearly believe Xenon Pharmaceuticals is more favorable than Supernus Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Supernus Pharmaceuticals 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 11 Buy rating(s) 1 Strong Buy rating(s) 3.08 SummarySupernus Pharmaceuticals beats Xenon Pharmaceuticals on 11 of the 19 factors compared between the two stocks. Ad Colonial MetalsTrump’s IRS Hands Massive ‘Victory Gift’ To 401K OwnersThe "Fake Media" has completely ignored Trump's genius "victory gift" to all America First patriots like you. A tax-free gift so powerful it could reshape the financial destinies of millions of IRA and 401(k) owners…Claim your FREE 2024 Gold Guide Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XENE vs. The Competition Export to ExcelMetricXenon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.96B$6.49B$5.07B$8.90BDividend YieldN/A8.11%4.99%4.07%P/E Ratio-13.954.8587.8613.46Price / Sales318.06374.821,228.8287.66Price / CashN/A52.5939.5136.27Price / Book3.7610.216.946.30Net Income-$182.39M$153.61M$119.12M$225.93M7 Day Performance-5.77%-2.00%-1.84%-1.32%1 Month Performance-11.02%-7.47%-3.65%0.60%1 Year Performance31.00%31.80%31.64%26.23% Xenon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XENEXenon Pharmaceuticals3.4958 of 5 stars$39.34+1.3%$57.45+46.0%+35.2%$2.96B$9.43M-13.95251Analyst RevisionSUPNSupernus Pharmaceuticals2.3042 of 5 stars$36.12+1.7%$36.00-0.3%+32.3%$1.96B$607.52M33.76580Positive NewsSAGESage Therapeutics4.2697 of 5 stars$4.91flat$12.89+162.5%-75.1%$300.36M$86.46M-0.88690Analyst ForecastNews CoverageGap DownVYGRVoyager Therapeutics4.6613 of 5 stars$5.36+1.7%$17.00+217.2%-21.6%$287.88M$250.01M7.55100Analyst UpgradeAnalyst RevisionGap UpOVIDOvid Therapeutics4.4265 of 5 stars$1.04+1.0%$4.04+288.5%-68.5%$73.14M$390,000.00-2.2160Analyst RevisionNews CoverageMRNSMarinus Pharmaceuticals4.4364 of 5 stars$0.31flat$4.79+1,448.8%-95.0%$16.97M$30.99M-0.13110Analyst ForecastAnalyst RevisionPCVXVaxcyte3.2938 of 5 stars$85.96-1.3%$147.50+71.6%+67.2%$10.85BN/A0.00160CTLTCatalent3.03 of 5 stars$59.00+0.2%$63.40+7.5%+47.8%$10.69B$4.38B0.0016,900SRPTSarepta Therapeutics4.914 of 5 stars$110.86+4.0%$181.33+63.6%+33.5%$10.18B$1.24B88.691,314Analyst DowngradeGap UpRVMDRevolution Medicines2.7869 of 5 stars$57.07+1.1%$61.00+6.9%+162.6%$9.50B$11.58M0.00443QGENQiagen4.4347 of 5 stars$42.11+3.2%$50.88+20.8%+2.5%$9.31B$1.97B107.975,967Positive NewsHigh Trading Volume Related Companies and Tools Related Companies Supernus Pharmaceuticals Alternatives Sage Therapeutics Alternatives Voyager Therapeutics Alternatives Ovid Therapeutics Alternatives Marinus Pharmaceuticals Alternatives Vaxcyte Alternatives Catalent Alternatives Sarepta Therapeutics Alternatives Revolution Medicines Alternatives Qiagen Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:XENE) was last updated on 11/21/2024 by MarketBeat.com Staff From Our PartnersMissed Nvidia? Watch this ASAPThis little-known project that Bill Gates has been quietly working on that’s about to unleash an AI breakthrou...Brownstone Research | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredUnveiled: NVIDIA’s "Secret Royalty" ProgramDid you know that there's an investment that will give you the opportunity to collect "royalties" every time N...Behind the Markets | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored24/7 Automated Profits in CryptoThe 4th quarter of 2024 is shaping up to be one of the most explosive periods for crypto in recent memory. But...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredBut another coin could soar even higher …Donald Trump wants to be America’s first crypto president. He was the keynote speaker at the recent Bitcoin co...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
